ClinicalTrials.gg
RecruitingNCT07084142Updated Apr 27, 2026

Developing a Digital Aid to Improve ICD Decisions

An interventional study of Online, patient-facing decision-making aid (app) with personalized risk information. and Implantable Cardioverter Defibrillator (ICD) in Heart Failure and Reduced Ejection Fraction, sponsored by Stanford University. Recruiting at 2 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Stanford University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Heart Failure, Systolic with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Heart Failure, Systolic · United States.

Planned enrollment
6th of 69
600 · median 40
Started
2025
with 5 others
No phase
44 of 83
9 open now
Primary completion
2026-08
later than 3 of 19 live
Registered
75th of 83
by date

Among the 83 studies in Heart Failure, Systolic with a site in United States, this one is the 6th largest by planned enrollment of the 69 interventional ones that give a count, is one of 6 that started in 2025, is one of 44 with no phase, reaches primary completion later than 3 of the 19 other live ones, and was the 75th registered.

Heart Failure, Systolic

230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.

Browse Heart Failure, Systolic studies →

Open to participants now

16 of the 83 studies in Heart Failure, Systolic with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Heart Failure, Systolic studies recruiting now, 18 (64%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Heart Failure, Systolic with a site in United States, or all of them as a file.
02

Study summary

Advanced heart failure, affecting 7 million Americans, has multiple causes and results in greatly increased risk of disability and death. A major problem is sudden cardiac death, when the damaged heart develops an abnormal pattern of electrical conduction that can result in cessation of heart activity. While placement of an Implantable Cardioverter-Defibrillator (ICD) in a patient's chest can help prevent sudden cardiac death, these devices have several important downsides. This protocol focuses on development of a digital decision aid that helps heart failure patients make informed decisions that balance the benefits and downsides of ICD placement. This protocol covers the use of participant surveys, focus groups, and interviews to obtain the needed background information to guide the development of this digital tool, which will be subsequently tested against usual care in a randomized clinical trial. The study design is best described as a mixed methods evaluation and refinement of a digital app to improve ICD decision-making. In the future, the present protocol will be modified to create a new protocol that covers the needed human subjects requirements for performance of this clinical trial.

Read the detailed description

Advanced heart failure, affecting 7 million Americans, has multiple causes and results in greatly increased risk of disability and death. A major problem is sudden cardiac death, when the damaged heart develops an abnormal pattern of electrical conduction that can result in cessation of heart activity. While placement of an Implantable Cardioverter-Defibrillator (ICD) in a patient's chest can help prevent sudden cardiac death, these devices have several important downsides. This protocol focuses on development of a digital decision aid that helps heart failure patients make informed decisions that balance the benefits and downsides of ICD placement. This protocol covers the use of participant surveys, focus groups, and interviews to obtain the needed background information to guide the development of this digital tool, which will be subsequently tested against usual care in a randomized clinical trial. In the future, the present protocol will be modified to create a new protocol that covers the needed human subjects requirements for performance of this clinical trial.

Participants with heart failure who agree to participate will be recorded in a REDCap system database. The investigators will document in a recruitment tracking log all potentially eligible participants found to be ineligible or who decline participation. The reason for ineligibility or reason for decline will be captured along with age, gender, and race/ethnicity. At the time of their enrollment, the investigators will collect additional information from each participant about their employment status (full-time or part-time employment, no employment, retired), education (no postsecondary education, some postsecondary education), household size (living alone, living with at least one other person).

Participants with heart failure will be asked if they are willing to be interviewed, participate in focus groups, or complete surveys to determine their views on 1) which elements of patient outcome questionnaires are important to them; 2) which decision aid components or educational tools they like or find valuable. Interactions with participants will include open-ended interviews, focus groups, and surveys. These interviews, focus groups, and surveys will be conducted by study staff to help develop a patient-centric shared decision making software tool. Development will occur iteratively with new testing after any modifications. The same individuals may be asked to re-test the app following alterations.

Collaborating teams from UC San Francisco (Site PI: Daniel Morin, MD, MPH) and East Carolina University (Site PI: Samuel Sears, PhD) will join the study before the third month of operation. The participation of these clinical sites is not needed in the first steps on digital tool development. By successfully initiating the project at Stanford, the process of initiation at the clinical sites will be facilitated and is consistent with the mandated use of a single IRB for the three sites.

03

Conditions studied

  • Heart Failure and Reduced Ejection Fraction

Keywords

  • heart failure
  • HFrEF
  • sudden cardiac death
  • patient education
  • shared decision-making
  • arrhythmia
  • implantable cardioverter-defibrillator
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Developmental Testing will attempt to abide by eligibility criteria identical to the planned criteria for the subsequent RCT, but may strategically deviate from these criteria to enhance the testing and development process.

Inclusion criteria

Inclusion Criteria:

  • Meets or approximates minimal criteria for primary prevention ICD placement. ● (LVEF) \<35%.
  • Clinical diagnosis of Heart Failure:
  • Patients with severe ischemic dilated cardiomyopathy and underlying
  • Class II or III Heart Failure, OR, Patients with severe nonischemic dilated cardiomyopathy and underlying NYHA Class II or III Heart Failure.
  • Age ≥ 70 years old.
  • Able to consent in English, Mandarin or Spanish and follow study instructions.

Exclusion criteria

Exclusion Criteria:

The exclusion criteria include any of the following:

  • Past ICD implantation (not including pacemakers).
  • Any indication for secondary prevention of SCD via ICD implantation.
  • History of mechanical valve replacement.
  • History of recent myocardial infarction within the last 40 days.
  • History of recent revascularization within the past 90 days.
  • History of familial or genetic disorders with a high-risk of ventricular arrhythmias, such as the long syndrome (LQTS) or hypertrophic cardiomyopathy (HCM).
  • Any factors contraindicating ICD placement.
  • Less than 6 months and other clinical consideration,
  • Unwilling or unable to consider ICD,
  • Any to ambulati
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Exposure to digital decision-making app with personal risk information

    The participant will use the pre-visit, participant-facing app with personal risk information derived from participant characteristics. During a clinical encounter, the clinician will have access to an abbreviated clinician-facing digital tool that displays the same personalized information.

    Other: Online, patient-facing decision-making aid (app) with personalized risk information. · Device: Implantable Cardioverter Defibrillator (ICD)

  • Experimental
    Use of a digital decision-making app without personalized risk information.

    The participant will use the pre-visit, participant-facing app without personal risk information. During a clinical encounter, the clinician will have access to an abbreviated clinician-facing digital tool.

    Device: Implantable Cardioverter Defibrillator (ICD) · Other: Online, patient-facing decision-making app without personalized risk information.

  • Placebo comparator
    Usual clinical care

    Participant will receive usual clinical care without use of the digital decision-making app.

    Device: Implantable Cardioverter Defibrillator (ICD)

Interventions

  • OtherOnline, patient-facing decision-making aid (app) with personalized risk information.

    The online, patient-facing decision-making aid will have the following features: 1. Clinical Data Input, 2. Introduction via Animated Video, 3. Common Questions, 4. Check-In Quiz, 5. Risk and Values Exploration based on patient specific information, 6. Wrap-Up, 7. Patient-Physician Worksheet, These steps will be completed by the patient in advance of a provider visit where a shared-decision making process will decide whether an ICD is an appropriate sudden cardiac death-prevention strategy to pursue.

  • DeviceImplantable Cardioverter Defibrillator (ICD)

    Some participants, in their course of medical care unrelated to the study intervention, will undergo implantation of an ICD.

  • OtherOnline, patient-facing decision-making app without personalized risk information.

    The online, patient-facing decision-making aid will have the following features: 1) Clinical Data Input, 2) Introduction via Animated Video, 3) Common Questions, 4) Check-In Quiz, 5) Generic Risk and Values Exploration without patient specific information, 6) Wrap-Up, 7) Patient-Physician Worksheet, These steps will be completed by the patient in advance of a provider visit where a shared-decision making process will decide whether an ICD is an appropriate sudden cardiac death-prevention strategy to pursue.

06

What researchers measure

Primary outcomes

  1. Decisional Conflict Scale (DCS)

    The Decisional Conflict Scale is a validated, 16-item questionnaire scale assessing whether a participant feels conflicted regarding a past medical decision. The range is 0 to 100 with higher scores indicating more conflict, a negative outcome.

    Time frame: Immediately after decision-making visit as well as at 3 months.

Other outcomes

  1. System Usability Scale (SUS)

    System Usability Scale (SAS) Standard Version is a metric for determining the ease of use of an online app. The app development process will focus on optimizing the user experience in each module of the proposed application. With a range of 0 to 100, a higher score is better. A score above 70 is considered acceptable.

    Time frame: Day 1 (SUS will be assessed immediately following testing of the app, or a specific module of the app)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Upon reasonable request after January 1, 2027, IPD will be provided without cost.

Supporting information: Study protocol

Time frame: IPD from this developmental stage will be available after January 1, 2027 for a period of at least 5 years.

Access criteria: Electronic access will be provided to IPD upon approval of reasonable requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.

Of 52 non-industry interventional studies with no phase under Heart Failure, Systolic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 56 studies reached it within 30 months; a quarter within 16 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Feb 2028
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07084142
Responsible party
Randall Stafford (Professor of Medicine, Stanford University) — Principal investigator
First posted
Jul 24, 2025
Start date
Aug 1, 2025
Primary completion
Aug 2026 (estimated)
Completion
Feb 2028 (estimated)
Last update
Apr 27, 2026

Study contacts

Randall S Stafford, MD, PhD, MHS
Contact
rstafford@stanford.edu
650-724-2400
Darlyne Esparza
Contact
desparza@stanford.edu
Randall S Stafford, MD, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion